C0544570||Anti-bacterial and Anti-biofilm Evaluation
C1254351||Thiazolopyrimidinone Derivatives
C0072399||Histidine Kinase
C1870317||YycG Protein of Staphylococcus epidermidis
C0038174||Staphylococcus epidermidis
C0205721||nosocomial infections
C0038174||S. epidermidis
C0081786||biofilms
C2735362||implanted medical devices
C0081786||biofilms
C0003232||antibiotics
C0020962||immune system
C0279516||anti-staphylococcal biofilm agents
C1254351||compound 5
C0072399||histidine kinase domain
C1870317||S. epidermidis YycG
C0544570||bactericidal activity
C0038174||staphylococci
C0243072||derivatives of compound 5 with intact thiazolopyrimidinone core structures
C0243072||7 derivatives
C0373483||screened
C0544570||anti-bacterial and anti-biofilm activities
C1254351||seven derivatives
C2244509||inhibited the growth
C0038174||S. epidermidis
C0038172||Staphylococcus aureus
C0427978||minimal inhibitory concentration
C0243072||derivatives
C0081786||biofilms
C0596402||cytotoxicity
C1512977||mammalian cells
C2945560||hemolytic
C0086418||human
C0014792||erythrocytes
C0081786||biofilm
C0243072||derivatives
C1254351||H5-32
C1254351||H5-33
C1254351||H5-34
C1254351||H5-35
C0081786||biofilm
C0038174||S. epidermidis
C1254351||seven derivatives of compound 5
C0081786||biofilm
C3714514||infections